Overview

Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999)

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
Nonrandomized, prospective, observational, multi-site registry to assess long-term safety, clinical outcome, deaths, and evolution of viral tropism in HIV subjects who completed or discontinued participation in Phase 2 or 3 clinical trials involving vicriviroc. Subjects will be followed for up to 5 years.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Emtricitabine
Maleic acid
Tenofovir